T he mission of the Food and Drug
Administration's (FDA) Center for Drug Evaluation and Research is to promote and protect public health by assuring that safe and effective drugs are available to Americans. Within this role, the FDA must provide practitioners with up-to-date information regarding the safety of medications approved by the agency. Some of this is achieved by announcements issued through the FDA's MedWATCH: The FDA Safety Information and Adverse Event Reporting Program, by changes in the drug labeling that can be found on the FDA Web site (http://www.fda.gov/medwatch/saf ety.htm), as well as changes made in the manufacturer's package inserts and labeling. However, some are questioning if consumers and health care professionals are starting to tune out the warnings issued by the FDA-very similar to the boy in the Aesop's fable entitled "The Boy Who Cried Wolf."
CNNMoney.com recently published a story entitled "Consumers Tune out FDA Warnings: A High Volume of Safety Alerts from the Nation's Drug Regulator has Doctors and Patients Wondering Just What to Believe." Within this story, it is stated that physicians and patients are suffocating from information saturation and that there are too many red flags for them to pay attention. 1 The FDA is caught in a difficult position. It needs to continue to warn consumers and health care professionals of the risks associated with medication, while maintaining a balance in the "benefit versus risk" aspect of their utilization. No medication is 100% safe. What are acceptable risks with one class of medication (eg, oncology products) are unacceptable risks with a different class of medication (eg, antidepressants or allergy medications). [2] [3] [4] [5] At what point do we need to be warned about a new risk? [5] [6] [7] Should the warning only occur when there is a definite cause-and-effect relationship established or when there is a potential warning sign that there may be a risk associated with the use of a particular medication?
For example, the latest warning regarding the potential increased risk of stroke in patients who used Spiriva is based on a safety analysis of pooled data from 29 placebo-controlled studies. 8 The preliminary results of the analysis estimate the risk of stroke with Spiriva therapy was 8 per 1,000 patients treated for 1 year compared to 6 per 1,000 patients treated for 1 year with placebo. If this difference is statistically different, then the number-needed-to-harm would be 500 people over this time frame. So, what is the appropriate threshold to trigger a warning or a change in product labeling? Each time a warning is issued and the news media reports it, 3 types of behavior may occur among the patients taking that particular medication 1, 9 : the first group might just ignore the warning and assume their prescriber will notify them if it is important; the second group immediately calls their prescriber's office or their pharmacist to seek additional information (unfortunately these health care professionals may not know about the new warning or may not have enough information to adequately evaluate the information at that time); while the third group decides to stop taking their medication and does not notify anyone of their decision. All 3 of these behaviors can have negative consequences; therefore, there needs to be a balance and health care professionals need to rapidly obtain reliable information when these announcements are issued.
The first step every health care professional should take is to subscribe to the FDA's MedWATCH news service (http://www.fda.gov/ medwatch/elist.htm). This tool delivers these announcements directly to health care providers via e-mail. The next step is to make it our responsibility to follow up on key announcements and stop ignoring them because we think there are too many red flags issued by the FDA.
